QLGN Multiplikator forward rega marang pendapatan Qualigen

Tandha merek Qualigen Therapeutics (QLGN)

Qualigen Therapeutics develops diagnostics and therapies to combat oncology and viruses, targeting global laboratory demand. The company's revenues are based on the sale of test systems, while future success depends on pharmaceutical developments. This GURU.Markets chart for the forward P/S ratio reflects a trend where 1.50 captures a new level. Optimized supply chains and insurance reserves guarantee logistical stability.

Qualigen Therapeutics, Inc. - Multiplikator Forward P/S QLGN (periode 04.07.2022 - 16.08.2024)

Rincian analitis perusahaan Qualigen Therapeutics

- rega pasar lan target rega analis:
Bagan rega Qualigen Therapeutics, Inc.|QLGN - Rentang target analis
- data kapitalisasi pasar:
Biji pasar Qualigen Corp|QLGN - Nilai Perusahaan
- rincian valuasi buku bisnis:
Nilai Buku saben Saham Qualigen Therapeutics|QLGN - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku qualigeninc.com|QLGN - Aset Agregat Perusahaan
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Qualigen Therapeutics|QLGN - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Qualigen Therapeutics|QLGN - Tanggungan utang total perusahaan|Utang-utang marang kapitalisasi buku Qualigen Corp|QLGN - Utang jangka dawa|Utang jangka cendhak perusahaan Qualigen Therapeutics|Indikator likuiditas cepet qualigeninc.com
- rincian asil keuangan lan kelipatan valuasi:
QLGN - Bathi pungkasan|Bathi mangsa ngarep Qualigen Therapeutics|QLGN - Rasio rega pasar marang bathi resik|Pangali Forward P/E Qualigen|QLGN - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Qualigen Corp|QLGN - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Qualigen Therapeutics|QLGN - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan qualigeninc.com|QLGN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Qualigen Therapeutics
- data total pendapatan lan volume dodolan:
QLGN - Pendapatan tahunan perusahaan|Prakiraan volume dodolan Qualigen Therapeutics, Inc.|QLGN - Rega marang dodolan|Multiplikator forward rega marang pendapatan Qualigen Corp
Analisis dhasar perusahaan:Qualigen Therapeutics, Inc. QLGN
Sampel barang Qualigen Corp

To assess the credit quality of Qualigen Therapeutics (QLGN), the analyst utilizes the company's forward P/S chart, which compares current market capitalization with expected revenue to identify whether the asset is overvalued or undervalued. The stability of this metric is supported by a clinical test outsourcing model coupled with full patent ownership, which reduces operational risks and allows the compression of the multiple to be interpreted as a signal to revise the investment risk profile.

Analisis pesaing

Rasio rega marang prakiraan pendapatan Gilead Sciences GILD|Prakiraan rega marang pendapatan Cidara Therapeutics Corp|NVAX: Multiplikator forward rega marang pendapatan|CVAC - Multiplikator Forward P/S|VALN: Multiplikator Forward P/S|vir.bio (VIR) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SIGA Technologies|Rasio rega marang prakiraan pendapatan EBS|Multiplikator Forward P/S AVIR|Rasio kapitalisasi marang dodolan sing dikarepake invivyd.com|Multiplikator Forward P/S ENTA (Enanta Pharmaceuticals)|Prakiraan rega marang pendapatan inovio.com|HilleVax - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kalaris Therapeutics Inc.|dyadic.com (DYAI) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan NNVC|Multiplikator forward rega marang pendapatan TLPH|COCP: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan TRAW (Traws Pharma, Inc.)|Rasio rega marang pendapatan sing dikarepake DWTX|Multiplikator Forward P/S ALVR (AlloVir)|Rega forward marang dodolan VBIV|Virios - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaxart, Inc.